
High-throughput, all-optical assay in human cardiomyoctes for clinically relevant prediction of drug induced cardiotoxityAward last edited on: 3/18/2025
Sponsored Program
SBIRAwarding Agency
NIH : NHLBITotal Award Amount
$5,135,397Award Phase
2Solicitation Topic Code
837Principal Investigator
Graham DempseyCompany Information
Phase I
Contract Number: 1R43HL126314-01Start Date: 11/15/2014 Completed: 5/14/2015
Phase I year
2015Phase I Amount
$221,686Public Health Relevance Statement:
Public Health Relevance:
Q-State's technology will allow better prediction of a drug candidate's potential adverse effect to human heart than the assays mandated by the current cardiac safety guidance ICH S7B. It will contribute to bringing effective healthcare solutions to market at lower cost and higher productivity, by preventing drugs with cardiotoxicity from reaching the market and preventing the development of valuable therapeutics from being wrongly terminated, which is one of the concerns about the current S7B assays. Making Q-State instrument and reagents available to the academic research community will facilitate better mechanistic studies and therapeutics development to benefit patients with cardiac conditions.
Project Terms:
Action Potentials; Adoption; Award; Biologic Assays; Bioassay; Assay; Biological Assay; Cells; Communities; Drug Preparation; Drug Compounding; drug/agent; Pharmaceutic Preparations; Medication; Drugs; Pharmaceutical Preparations; Neurophysiology / Electrophysiology; Electrophysiology; Electrophysiology (science); Environmental Health Science; Environmental Health; Fluorescence; Genes; Heart; Modern Man; Man (Taxonomy); Human; In Vitro; Institutes; instrumentation; heavy metal lead; heavy metal Pb; Pb element; Lead; Photoradiation; Light; Manuals; Marketing; Methods; neuronal; Neurocyte; Neural Cell; Nerve Unit; Nerve Cells; Neurons; optical; Optics; Patients; Productivity; Public Health; public health medicine (field); Reagent; Research; Risk; Safety; biological signal transduction; Signaling; Signal Transduction Systems; Intracellular Communication and Signaling; Cell Signaling; Cell Communication and Signaling; Signal Transduction; computer program/software; Software; Computer software; Solutions; Technology; Testing; Time; Torsades de Pointes; USFDA; Food and Drug Administration; United States Food and Drug Administration; Iproveratril; Benzeneacetonitrile, alpha-(3-((2-(3, 4-dimethoxyphenyl)ethyl)methylamino)propyl)-3, 4-dimethoxy-alpha-(1-methylethyl)-; Verapamil; Measures; Drug Delivery Systems; Drug Delivery; health care; Healthcare; Promotor; Promoters (Genetics); Promoter; Promotor (Genetics); base; Acute; Chronic; Phase; Variation; Variant; Evaluation; cardiomyocyte; Heart myocyte; Heart Muscle Cells; Cardiocyte; Cardiac Muscle Cells; Cardiac Myocytes; Stimulus; Withdrawal; Measurement; Funding; Therapeutic; Staging; Reporter; tool; instrument; Msec; millisecond; Protocol; Protocols documentation; LOINC Axis 4 System; System; Services; innovative technologies; experience; membrane structure; Membrane; success; V (voltage); voltage; trafficking; Speed; Speed (motion); Modality; assay development; Cardiac Toxicity; Cardiotoxicity; treatment adverse effect; therapy adverse effect; side effect; Treatment Side Effects; Adverse effects; drug discovery; patch clamp; preventing; prevent; Address; Resolution; Small Business Innovation Research; SBIRS (R43/44); SBIR; Small Business Innovation Research Grant; Molecular; Cardiac; Gene Delivery; developmental; Development; Phototoxicity; cell imaging; cellular imaging; NINDS; National Institute of Neurological Disorders and Stroke; cost; software systems; imaging Segmentation; iPSC; iPS; induced pluripotent stem cell; therapeutic development; public health relevance; product development; drug candidate; Regimen; screening
Phase II
Contract Number: 2R44HL126314-02A1Start Date: 11/15/2014 Completed: 3/31/2018
Phase II year
2016(last award dollars: 2023)
Phase II Amount
$4,913,711Public Health Relevance Statement:
Public Health Relevance:
QÂ"State's technology will allow better prediction of a drug candidate's potential adverse effects to the human heart than the assays mandated by the current cardiac safety guidance ICH S7B. It will contribute to bringing effective healthcare solutions to market at lower cost and higher productivity, by preventing drugs with cardiotoxicity from reaching the market and preventing the development of valuable therapeutics from being wrongly terminated, which is one of the concerns about the current S7B assays. Making Q-Â"State instrumentation and reagents available to the academic research community will facilitate better mechanistic studies and therapeutics development to benefit patients with cardiac conditions.
Project Terms:
Accounting; Action Potentials; adulthood; Adult Human; 21+ years old; Adult; Algorithms; Heart Arrhythmias; Cardiac Arrhythmia; Arrhythmia; Award; Biologic Assays; Bioassay; Assay; Biological Assay; Life Sciences; Bioscience; Biologic Sciences; Biological Sciences; Factor IV; Coagulation Factor IV; Ca++ element; Blood Coagulation Factor IV; Calcium; circulatory system; Heart Vascular; Cardiovascular Organ System; Cardiovascular Body System; Cardiovascular; Cardio-vascular; Cardiovascular system; Cell Body; Cells; Communities; drug treatment; Drug Therapy; Pharmacotherapy; drug/agent; Pharmaceutic Preparations; Medication; Drugs; Pharmaceutical Preparations; electrophysiological; Neurophysiology / Electrophysiology; Electrophysiology; Electrophysiology (science); Engineering; Environmental Health Science; Environmental Health; Heart; Modern Man; Human; In Vitro; Institutes; instrumentation; Membrane Channels; Ionic Channels; Ion Channel; heavy metal lead; heavy metal Pb; Pb element; Lead; Manuals; Marketing; optical; Optics; Paper; Patients; Potassium Ion Channels; K channel; Potassium Channel; Production; Productivity; Proteins; Reagent; Research; Risk; Safety; Sensitivity and Specificity; Computer Software Engineering; Computer Software Development; Software Engineering; Technology; Testing; Time; Torsades de Pointes; Transcription; RNA Expression; Gene Transcription; Genetic Transcription; United States Food and Drug Administration; USFDA; Food and Drug Administration; Vendor; Work; Measures; Healthcare; health care; Blinded; Acute; Chronic; Clinical; Phase; Link; cardiomyocyte; Heart myocyte; Heart Muscle Cells; Cardiocyte; Cardiac Muscle Cells; Cardiac Myocytes; Measurement; Funding; Collaborations; Therapeutic; Staging; Contracting Opportunities; Contracts; Reporter; tool; instrument; support vector machine; statistical learning; kernel methods; Machine Learning; Hour; Frequencies; Protocol; Protocols documentation; Source; Techniques; System; Services; success; voltage; Toxicities; Toxic effect; Reporting; Position; Positioning Attribute; Modeling; Human Nature; Human Characteristics; response; Cardiotoxic; Cardiac Toxicity; Cardiotoxicity; treatment adverse effect; therapy adverse effect; side effect; Treatment Side Effects; Adverse effects; drug discovery; patch clamp; Provider; preventing; prevent; Address; Data; Detection; molecular signature; molecular profile; Molecular Fingerprinting; Expression Profiling; Molecular Profiling; Resolution; in vitro Model; Cell Maturation; Characteristics; Molecular; Cardiac; developmental; Development; Phototoxicity; imaging; Image; human stem cells; cost; Outcome; clinically relevant; clinical relevance; novel therapeutics; novel therapy; novel drugs; novel drug treatments; next generation therapeutics; new therapy; new therapeutics; new drugs; new drug treatments; induced pluripotent stem cell; iPSCs; iPSC; iPS; spatiotemporal; therapeutic development; public health relevance; stem cell biology; drug candidate; phase 1 study; Phase I Study; optogenetics; screening; Geometry; rate of change; prediction algorithm; predictor algorithm; predictive algorithm